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Abstract
Background: The prevalence of mood difficulties in persons with diabetes is approximately twice that in the
general population, affecting the health outcomes and patients’ quality of life in an undesirable way. Although
subsyndromal depression is an important predictor of a more serious clinical depression, it is often overlooked. This
study aims to compare the effects of two non-pharmacological interventions for subsyndromal depression,
psychoeducation and physical exercise, with diabetes treatment as usual on mood- and diabetes-related outcomes.
Methods and Design: Type 2 diabetic patients aged 18-65 yrs. who report mood difficulties and the related need
for help in a mail survey will be potential participants. After giving informed consent, they will be randomly
assigned to one of the three groups (psychoeducation, physical activity, treatment as usual). Depressive symptoms,
diabetes distress, health-related quality of life and diabetes self-care activities will be assessed at baseline, at
6 weeks, 6 months and 12 months. A structured clinical interview for DSM-IV Axis I Disorders (SCID-I) will be
performed at baseline and at one-year follow-up in order to determine the clinical significance of the patients’
depressive symptoms. Disease-related data will be collected from patients’ files and from additional physical
examinations and laboratory tests.
The two interventions will be comparable in terms of format (small group work), duration (six sessions) and
approach (interactive learning; supporting the participants’ active roles). The group treated as usual will be
informed about their screening results and about the importance of treating depression. They will be provided
with brief re-education on diabetes and written self-help instructions to cope with mood difficulties.
Primary outcomes will be depressive symptoms. Secondary outcomes will be glycaemic control, diabetes-related
distress, self-management of diabetes and health-related quality of life. Tertiary outcomes will be biochemical
markers reflecting common pathophysiological processes of insulin resistance, inflammation and oxidative damage
that are assumed to be intertwined in both diabetes and depression. The mixed-effect linear model will be used to
compare the outcome variables.
Power analysis has indicated that the two intervention groups and the control group should comprise 59 patients
to enable detection of clinically meaningful differences in depressive symptoms with a power of 80% and alpha =
0.05. Outcomes will be analysed on an intention-to-treat basis.
Trial Registration: ISRCTN: ISRCTN05673017
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The prevalence of clinical depression in diabetic patients
is approximately twice that in the general population
[1]. The literature data have consistently demonstrated a
synergistic interaction between diabetes and depression
that increases the risk for poor health outcomes [2].
Compared to patients with diabetes alone, patients with
depression and diabetes have poorer self-management
(i.e. adherence to diet, exercise regimen and blood
glucose monitoring) and significantly more lapses in
refilling oral hypoglycaemic, lipid-lowering and antihy-
pertensive prescriptions [3,4]. They are also significantly
more likely to have cardiac risk factors such as smoking,
obesity and sedentary lifestyle [5]. Depression is asso-
ciated with an increased risk of metabolic dysregulation
[6], micro- and macrovascular complications [7], and
mortality [8]. However, despite the clear evidence of an
undesirable interaction between depression and diabetes,
depression remains unrecognised in approximately one
half of diabetic patients, and is consequently not treated
properly [9].
Both psychiatric medication [10-12] and psychological
interventions [13-16] have been proven to be efficient in
alleviating depression in diabetic patients. However, the
effects of pharmacological treatment of depression on
glycaemic control remain unclear, with some trials
pointing to adverse effects, and some reporting on mod-
est positive effects on HbA1c values. Trials relying on
cognitive behavioural therapy and counselling for
depression have shown moderate to good effects on gly-
caemic control [13-15]. An exception is the study by
Georgiades et al. [17], which demonstrated that changes
in depressive symptoms after a cognitive behavioural
therapy intervention were not associated with changes
in HbA1c values over a one-year period.
Recent research has suggested that subsyndromal
depression, defined as the presence of depressive symp-
toms that fall short of full diagnostic criteria for major
depression or dysthymia, has a profound influence on
the affected patients’ quality of life and may be a part of
a continuum of depressive disorders [18,19]. Data from
the general population indicate that spontaneous remis-
sion rates for this type of mood disturbance are low
[20]. Subsyndromal depression was found to increase
the risk of subsequent major depression [21] and suicide
[22]. Chronic illness and medical burden are among the
predictors of conversion from minor depression into its
more severe clinical forms [23,24]. Treating depression
in diabetic patients at its early stages may therefore be
beneficial for improving both the affected patients’
mood and the self-management of diabetes.
Studies exploring the effects of treatment for mild to
moderate depression in diabetic patients are scarce,
although this form of depression is highly prevalent in
the diabetic population [1]. However, both pharmaco-
logical treatment [25] and psychoeducation [26,27]
appear to be promising as treatment for mild depres-
sion and for improving glycaemic control in these
patients. Physical activity has been demonstrated to
alleviate depressive symptoms in the non-diabetic
population as efficiently as cognitive behavioural
therapy [28]. Lack of exercise in diabetic patients is
associated with 72% to 75% higher likelihood of being
depressed [29]. Two randomised trials have examined
the impact of a depression-specific intervention on
exercise patterns in persons with type 2 diabetes. They
have provided equivocal support for the impact, one
suggesting an increase in physical activity [15] and the
other reporting no such change [30].
Research on the treatment of subsyndromal depres-
sion in patients with diabetes is scant, allowing no
conclusion about its effects on depression- and diabetes-
related outcomes. Due to a small number of studies in
the field, it remains unclear whether some non-pharma-
cological therapeutic approaches may be superior to
others.
T h e r ei sa ni n c r e a s i n gb o d yo fe v i d e n c ei m p l y i n g
chronic inflammation as an important link between
diabetes and depression [31]. Activation of innate
immunity and complex changes in inflammatory pat-
terns have been found to play a significant role in the
pathogenesis of type 2 diabetes and insulin resistance
[32], and a recent hypothesis on the pivotal role of
inflammatory cytokines and oxidative/nitrosative
stress in the pathogenesis of depression has recieved
much attention [33]. Whether or not inflammatory
response and the resulting oxidative damage in dia-
betes is primary or reactive is not clear, but its signif-
icant association with both insulin resistance and
beta cell dysfunction, as well as with many different
co-morbidities (atherosclerosis, obesity, depression),
definitively suggests that the activation of innate
immunity should be regarded as more than just an
epiphenomenon.
Despite an accumulating body of evidence suggesting
that changes in inflammatory and pro-/anti-oxidative
biomarkers in diabetes and clinical depression are sepa-
rate entities, little is known on the possible involvement
of these complex processes in diabetic patients with
subsyndromal depression. Our study aims to investigate
whether non-pharmacological intervention for subsyn-
dromal depression, apart from the hypothesised allevia-
tion of depressive symptoms and improvement in
glycaemic control, could offer additional benefit to dia-
betic patients by reducing chronic inflammation and
oxidative damage.
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Objective
The aim of this paper is to present a research protocol of a
randomised controlled trial designed to compare two non-
pharmacological interventions for subsyndromal depres-
sion (psychoeducation and physical activity) with diabetes
treatment as usual. We hypothesise that the two interven-
tions will be superior to treatment as usual in reducing
depressive symptoms and improving diabetes control.
Design
Type 2 diabetic patients will be randomised to a six-
week psycho-educational intervention, a six-week physi-
cal activity intervention, or diabetes treatment as usual.
The study diagram is presented in Figure 1.
Setting
The study will be conducted in a specialised diabetes
clinic (The Vuk Vrhovac University Clinic for Diabetes,
Endocrinology and Metabolic Diseases) that is a part of
a teaching hospital (Merkur Teaching Hospital) affiliated
with the University of Zagreb in Croatia.
Inclusion criteria
The eligible participants have to meet all of the follow-
ing criteria:
￿ type 2 diabetic patients
￿ aged 18-65 yrs.
￿ attended a regular check-up in the Clinic during
the previous year
￿ living in Zagreb
￿ self-reported mood difficulties on PHQ-2 in a mail
survey
￿ expressed the need for additional help regarding
mood difficulties
Exclusion criteria
￿ poor literacy and/or lack of fluency in Croatian
language
￿ mobility difficulties
￿ visual impairment
￿ current major depressive disorder
￿ current or history of alcohol abuse, bipolar or psy-
chotic disorder
￿ medical contraindications for physical exercise
(heart attack or stroke during the past 12 months,
angina pectoris)
Recruitment and baseline
A standardised two-item screening instrument, the
Patient Health Questionnaire (PHQ-2) that includes an
additional question inquiring into patients’ need to
receive help in mood-related issues [34] will be sent to
all potential study participants retrieved from a database
of diabetic patients [35]. Participants will be provided
w i t har e p l y - p a i de n v e l o p ef o rt h er e t u r no ft h ec o m -
pleted questionnaire. They will also be asked for permis-
sion to be contacted by telephone if they indicate that
they are interested in receiving help.
Participants who return the questionnaire reporting
mood difficulties and the need for help will be telephoned
for the assessment of exclusion criteria. Those whose sta-
tus of contraindications for exercise is unclear will be
offered a medical examination by the Clinic’s internist,
who will determine whether this exclusion criterion is
met. The potential participants will be interviewed for a
clinical diagnosis of depression. SCID-I (Structured Clini-
cal Interview for the DSM-IV Axis I Disorders) will be
administered by a trained researcher by telephone, as this
method has proved to be comparable to the face-to-face
interview [36]. Patients who meet the criteria for the diag-
nosis of major depression will be advised to refer to their
GP or psychiatrist and will be excluded from the trial,
since they require more intensive treatment. The eligible
patients will be offered an appointment with the research-
ers to give informed consent, provide data and be
informed of the group assignment.
Randomisation
This study design has three arms: psycho-educational
intervention, physical activity intervention, and depres-
sion screening followed by diabetes treatment as usual.
Eligible participants will be randomised into one of the
three groups by using a computer-assisted approach.
Groups will be balanced by age and sex. Randomisation
will be carried out by a member of the team who will
not take part in the treatment. Data on patients (SCID-I
assessment, baseline and follow-up data) will be col-
lected by team members unaware of the patients’ group
assignment. Baseline and one-year follow-up structured
clinical interview (SCID-I) will be administered by the
same person on both occasions.
Interventions
Psychoeducation
The intervention will comprise 6 interactive small-group
meetings (4-6 members), each lasting for 60-90 minutes.
The topics will include: interaction of depression and
diabetes; alleviating burden of depression through activ-
ities and problem solving; associations between depres-
sion and cognitive processes - thoughts, beliefs and
attitudes that induce and maintain depression; gaining
social support and developing a personal plan for mana-
ging problems in the future.
Meetings will be held at weekly intervals. The sessions
will combine a short standardised presentation focused
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assignments. Patients will be provided with a self-help
manual for overcoming depressive difficulties based on
the “Coping with depression” course by P.M. Lewinsohn.
The manual is structured in a way that facilitates intro-
ducing personal examples and making notes. The “Cop-
ing with depression” programme is well-evaluated in
both general population and medical patients [37]. For
the purpose of this study, the programme has been
adjusted to address specific emotional problems related
to diabetes and adapted for a shorter format of this
intervention. Patients will also receive a workbook con-
taining exercises to recognise depressive symptoms,
become aware of daily activity patterns, acquire
 
S
h
o
r
t
-
t
e
r
m
 
p
h
a
s
e
:
 
P
s
y
c
h
o
-
e
d
u
c
a
t
i
o
n
 
v
s
.
 
p
h
y
s
i
c
a
l
 
a
c
t
i
v
i
t
y
 
v
s
.
 
s
c
r
e
e
n
i
n
g
 
w
i
t
h
 
t
r
e
a
t
m
e
n
t
 
a
s
 
u
s
u
a
l
 
w
i
t
h
i
n
 
8
 
w
e
e
k
s
 
 
Screening 
Exclusion criteria 
Informed consent 
↓ 
Randomisation 
↓ 
T0: Baseline data 
Depression  
Diabetes-related distress 
Self-care behaviours 
Health-related quality of life 
Physical activity level 
Medical status  
HbA1c, lipids, albumin/creatinine ratio, BP, BMI, WHR 
Insulin, HOMA-2IR, 8-OH-guanine, MDA, CRP-HS, sialic acid, uric acid, CBC-5DIFF 
Pain self-assessment 
Psychosocial history 
↓  ↓  ↓ 
Physical activity intervention 
Depression screening 
followed by diabetes 
treatment as usual 
Psycho-education 
↓  ↓  ↓ 
T1: post-treatment 
Depressive symptoms 
Diabetes-related distress 
Self-care behaviours 
Health-related quality of life 
Physical activity level 
HbA1c, lipids, albumin/creatinine ratio, BP, BMI, WHR 
Pain self-assessment 
Patient enablement 
    ↓ 
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T2: 6-month follow-up 
Depressive symptoms 
Diabetes-related distress 
Self-care behaviours 
Health-related quality of life  
Physical activity level 
HbA1c, lipids, albumin/creatinine ratio, BP, BMI, WHR 
Insulin, HOMA-2IR, 8-OH-guanine, MDA, CRP-HS, sialic acid, uric acid, CBC-5DIFF 
Pain self-assessment 
↓ 
T3: 12-month follow-up 
Major depressive disorder/dysthymia 
Depressive symptoms 
Diabetes-related distress 
Self-care behaviours 
Health-related quality of life  
Physical activity level 
HbA1c, lipids, albumin/creatinine ratio, BP, BMI, WHR 
Insulin, HOMA-2IR, 8-OH-guanine, MDA, CRP-HS, sialic acid, uric acid, CBC-5DIFF 
Pain self-assessment 
 
Figure 1 Study diagram.
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cognitive patterns that contribute to the maintenance
of depression. The manual was tested for comprehensi-
bility and clarity in a group of diabetic patients (N =
8) with different demographic and disease-related
characteristics.
Physical activity
The intervention will comprise 6 weekly small-group
sessions. The purpose of these sessions will be to edu-
cate patients about the interaction of physical activity,
mood and diabetes, and to increase their participation
in a variety of physical activities with an emphasis on
walking. The sessions will combine interactive lectures
and exercise techniques (warm-up, flexibility, strength-
ening and stretching exercises) that are considered sui-
table for the study participants. The educational topics
will include effects of exercise on mood; short- and
long-term effects of exercise on blood glucose and the
cardiovascular system; and strategies to develop and
maintain a personal plan for regular exercise. The pro-
gramme has been developed by a professional trainer
experienced in working with the diabetic population.
The sessions will be organised in a group format and
led by a professional trainer. Exercise intensity will be
measured by a heart rate monitor and maintained in a
light-to-medium intensity range. The volume of physical
activity will be monitored by a pedometer for one week
preceding each point of measurement.
Depression screening followed by diabetes treatment
as usual
The patients screened for depression will be given an
explanation of their results and informed about the
importance of treating depression, as well as about dif-
ferent treatment options. They will be provided with
brief re-education on diabetes aimed at alleviating dia-
betes-related burden, and with written self-help instruc-
tions to cope with mood difficulties.
Follow-up data will be collected at the same points of
measurement as in the treatment groups.
Assessments
Patients will be assessed at four time points: at baseline
( T 0 ) ,a tt h ee n do ft h ei n t e r v entions (i.e., 6 weeks after
the beginning, T1), at 6 months (T2) and at 12 months
(T3) after the beginning of the intervention (Figure 2).
Data will be collected by experienced researchers
blinded to group assignment.
Data concerning the patients’ psychological history
(psychological morbidity, treatment method, symptom
course, family history of psychiatric morbidity) and cur-
rent psychosocial situation (family and professional sta-
tus, economic circumstances, recent stress experiences,
perceived social support) will be collected at baseline by
semi-structured telephone interview.
Psychological questionnaires will be applied at all
points of measurement to collect data on patients’ emo-
tional state and their experience in living with diabetes:
depressive symptoms (Center for Epidemiologic Studies
Depression Scale, CES-D), diabetes distress (Problem
Areas in Diabetes, PAID), health-related quality of life
(Short Form Survey, SF-12) and diabetes self-care (Sum-
mary of Diabetes Self-Care Activities, SDSCA). The
questionnaires have been psychometrically evaluated in
Croatian diabetic patients. SCID-I will be re-adminis-
tered after 12 months.
To assess the level of physical activity, a subscale of
the Summary of Diabetes Self-Care Activities (SDSCA)
referring to the frequency and intensity of physical activ-
ity during previous week will be applied at all measure-
ment points. To provide objective data, patients from
both the intervention groups and the control group will
wear the pedometer for one week preceding all points
of measurement, including the baseline.
Baseline information on the type, duration and treat-
ment of diabetes, body mass index (BMI), waist-to-hip
ratio (WHR), and concomitant somatic diseases will be
retrieved from the patients’ medical records. If neces-
sary, an internist will be consulted about the interpre-
tation of data. Biochemical parameters including
HbA1c, lipids, and albumin/creatinine ratio, and data
on patients’ body weight, blood pressure and diabetes
medication will be determined and recorded at all
points of measurement. Fasting plasma glucose and
insulin will be used to assess insulin resistance by a
HOMA-2IR model [38]. Low-grade inflammation will
be monitored by high sensitivity C-reactive protein,
total sialic acid [39], WBC and neutrophil counts.
Urinary 8-hydroxy-2’-deoxyguanosine and serum
malondialdehyde and 4-hydroxyalkenals will be used as
biomarkers of DNA and lipid oxidative damage,
respectively, whereas uric acid as the most prominent
low-molecular weight endogenous antioxidant will be
measured by an automated enzymatic technique at T0,
T2 and T3, to avoid possible short-term biological
interferences of exercise.
Patients will provide their self-monitoring blood glu-
cose (SMBG) records kept in accordance with their
treatment algorithms and recommendations over the
whole study period.
Due to a possible interaction between depression and
neuropathic pain, patient self-assessments of neuro-
pathic pain will be evaluated by a simple visual analogue
scale at all points of measurement.
Indicators of glycaemic control (HbA1c) will be deter-
mined by an automated immunoturbidimetric method
using commercially available reagents (Roche Diagnos-
tics), traceable to the NGSP/DCCT standard, with a
total imprecision (CV) of 2.8%.
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(psychoeducation, physical activity intervention, treat-
ment as usual) will be recorded. Although it is assumed
that this might influence drop out, adherence and inter-
vention impact, the methodological benefits of randomi-
sation outweigh the potential costs. Possible effects of
treatment preference on outcome measures will be con-
trolled for statistically.
Outcome measures
Primary outcome measures
T h ep r i m a r ys t u d yo u t c o m e sw i l lb ed e p r e s s i v es y m p -
toms as measured by the CES-D.
Secondary outcome measures
Secondary outcomes will be self-management of dia-
betes, glycaemic control, diabetes-related distress and
health-related quality of life measured as described
previously.
Tertiary outcome measures
Tertiary outcomes will be biochemical markers reflect-
ing common pathophysiological processes of insulin
resistance, inflammation and oxidative damage that are
assumed to be intertwined in both diabetes and
depression.
Data analysis
Continuous data will be summarized for each group
using descriptive statistics. The distributions of continu-
ous data at the follow-up assessments will be compared
by the linear mixed-effects model the flexibility of which
m a k e si tt h ep r e f e r r e dc h o i c ef o rt h ea n a l y s i so f
repeated-measures data.
  SCREENING  BASELINE  TREATMENT PERIOD 
(weeks) 
FOLLOW-
UP 
(months) 
      -1  1  2  3  4  5  6  +1  6  12 
Inclusion/exclusion criteria  x                       
Patient demography, medical 
and psychological history  
  x                     
Informed consent  x                       
Structured clinical interview 
(DSM-IV Axis 1) 
x                      x 
Randomisation  x                       
Physical examination  x*                       
Center for Epidemiological 
Studies-Depression (CES-D) 
  x                x  x  x 
Problem Areas in Diabetes 
(PAID) 
  x                x  x  x 
Health-Related Quality of 
Life Short-Form Survey (SF-
12) 
  x                x  x  x 
Diabetes Self-Care Activities 
(DSCA) 
  x                x  x  x 
Self-assessment of 
neurological pain (VAS) 
  x                x  x  x 
HbA1c, lipids, 
albumin/creatinine ratio, BP, 
BMI, WHR 
  x                x  x  x 
Insulin, HOMA-2IR, 8-OH-
guanine, MDA, CRP-HS, 
sialic acid, uric acid, CBC-
5DIFF 
  x                  x  x 
Physical activity monitoring 
– (pedometer) 
  x  x              x  x  x 
Psycho-educational group 
meetings 
      x  x  x  x  x  x       
Physical activity group 
meetings 
      x  x  x  x  x  x       
Patient Enablement 
Instrument (PEI) 
                  x     
* when needed to establish eligibility for participation 
Figure 2 Study flowchart.
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ment group using counts and percentages. The distribu-
tions of categorical data in each treatment group will be
compared using the Pearson Chi-square test.
In addition to the effects of intervention on psycholo-
gical and biomedical outcome variables, data on partici-
pation rate among eligible individuals (intervention
reach) will be considered relevant.
All analyses will be performed by StatSoft Statistica
version 7.0.
Ethical aspects
The study protocol has been approved by the Vuk
Vrhovac University Clinic’s Ethics Committee. Patients
will be provided with information about this trial, their
rights and the data to be collected from them, and a
written informed consent will be obtained from all
participants.
Abbreviations
HbA1c: glycated haemoglobin; PHQ-2: Patient Health Questionnaire; SCID-I:
Structured Clinical Interview for the DSM-IV Axis I Disorders; GP: general
practitioner; CES-D: Center for Epidemiologic Studies Depression Scale; PAID:
Problem Areas in Diabetes; SF-12: Short Form Survey; SDSCA: Summary of
Diabetes Self-Care Activities; BMI: body mass index; WHR: waist-to-hip ratio;
WBC: white blood cell count; DNA: deoxyribonucleic acid; SMBG: self-
monitoring blood glucose
Acknowledgements
Funding for this study was provided by a grant from the European
Foundation for the Study of Diabetes New Horizons Collaborative Research
Initiative.
The authors wish to thank Manja Prašek, MD, Željko Metelko, MD, PhD, and
Jadranka Kos, MA, for their assistance in planning this research project, and
Lovorka Perković for her help with the editing of the manuscript.
Author details
1Team for Mental Health, Vuk Vrhovac University Clinic for Diabetes,
Endocrinology and Metabolic Diseases, Merkur Teaching Hospital, University
of Zagreb, Zagreb, Croatia.
2Institute of Clinical Chemistry and Laboratory
Medicine, Merkur Teaching Hospital, University of Zagreb, Zagreb, Croatia.
3Research Institute of the Diabetes Academy Mergentheim, Bad
Mergentheim, Germany.
Authors’ contributions
All authors collaborated on the development of the study design. MPO is
responsible for devising the interventions. MPO, DA, and MVL planned the
study outcomes and their collection. MPO and DA wrote the initial draft of
the manuscript. NH contributed in preparing and reviewing the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 26 November 2010 Accepted: 21 January 2011
Published: 21 January 2011
References
1. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ: The prevalence of
co-morbid depression in adults with diabetes. Diabetes Care 2001,
24:1069-1078.
2. Black SA, Markides KS, Ray LA: Depression predicts increased incidence of
adverse health outcomes in older Mexican Americans with type 2
diabetes. Diabetes Care 2003, 26:2822-2828.
3. Ciechanowski PS, Katon WJ, Russo JE: Depression and diabetes: impact on
adherence, function and costs. Arch Intern Med 2000, 160:3278-3285.
4. Lin EH, Katon W, Von Korff M, Rutter C, Simon GE, Oliver M, Ciechanowski P,
Ludman EJ, Bush T, Young B: Relationship of depression and diabetes
self-care, medication adherence and preventive care. Diabetes Care 2004,
27:2154-2160.
5. Katon WJ, Lin EH, Russo J, Von Korff M, Ciechanowski P, Simon G,
Ludman E, Bush T, Young B: Cardiac risk factors in patients with diabetes
mellitus and major depression. J Gen Intern Med 2004, 19:1192-1199.
6. Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM:
Depression and poor glycemic control: a meta analytic review of the
literature. Diabetes Care 2000, 23:434-442.
7. De Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ: Association
of depression and diabetes complications: a meta-analysis. Psychosom
Med 2001, 63:619-630.
8. Katon WJ, Rutter C, Simon G, Lin EH, Ludman E, Ciechanowski P, Kinder L,
Young B, Von Korff M: The association of comorbid depression with
mortality in patients with type 2 diabetes. Diabetes Care 2005,
28:2668-2672.
9. Pouwer F, Beekman ATF, Lubach C, Snoek FJ: Nurses recognition and
registration of depression, anxiety, and diabetes-specific emotional
problems in outpatients with diabetes mellitus. Patient Educ Couns 2006,
60:235-240.
10. Lustman PJ, Griffith LS, Clouse RE, Freedland KE, Eisen SA, Rubin EH,
Carney RM, McGill JB: Effects of nortriptyline on depression and glycemic
control in diabetes: results of a double-blind, placebo-controlled trial.
Psychosom Med 1997, 59:241-250.
11. Lustman PJ, Freedland KE, Griffith LS, Clouse RE: Fluoxetine for depression
in diabetes: a randomized double-blind placebo-controlled trial. Diabetes
Care 2000, 23(5):618-623.
12. Lustman PJ, Clouse RE, Nix BD, Freedland KE, Rubin EH, McGill JB,
Williams MM, Gelenberg AJ, Ciechanowski PS, Hirsch IB: Sertraline for
prevention of depression recurrence in diabetes mellitus: a randomized,
double-blind, placebo-controlled trial. Arch Gen Psychiatry 2006,
63:521-529.
13. Huang X, Song L, Li T: The effect of social support on type II diabetes
with depression. Chinese Journal of Clinical Psychology 2001, 9:187-189.
14. Lustman PJ, Griffith LS, Freedland KE, Kissel SS, Clouse RE: Cognitive
behavior therapy for depression in type 2 diabetes mellitus. A
randomized, controlled trial. Ann Intern Med 1998, 129:613-621.
15. Williams JW Jr, Katon W, Lin EH, Nöel PH, Worchel J, Cornell J, Harpole L,
Fultz BA, Hunkeler E, Mika VS, Unützer J, IMPACT Investigators: The
effectiveness of depression care management on diabetes-related
outcomes in older patients. Ann Intern Med 2004, 140:1015-1024.
16. Katon WJ, Von Korff M, Lin EH, Simon G, Ludman E, Russo J,
Ciechanowski P, Walker E, Bush T: The Pathways study: a randomized trial
of collaborative care in patients with diabetes and depression. Arch Gen
Psychiatry 2004, 61:1042-1049.
17. Georgiades A, Zucher N, Friedman KE, Mosunic CJ, Applegate K, Lane JD,
Feinglos MN, Surwit RS: Changes in depressive symptoms and glycemic
control in diabetes mellitus. Psychosom Med 2007, 69:235-241.
18. Goldney RD, Phillips PJ, Fisher LJ, Wilson DH: Diabetes, depression and
quality of life. Diabetes Care 2004, 27:1066-1070.
19. Rapaport M, Clary C, Fayyad R, Endicott J: Quality of life impairment
in depressive and anxiety disorders. Am J Psychiatry 2005,
162:1171-1178.
20. Hegel MT, Oxman TE, Hull JG, Swain K, Swick H: Watchful waiting for
minor depression in primary care: remission rates and predictors of
improvement. Gen Hosp Psychiatry 2006, 28(3):205-212.
21. Cuijpers P, Smit F: Subthreshold depression as a risk indicator for major
depressive disorder: a systematic review of prospective studies. Acta
Psychiatr Scand 2004, 109:325-331.
22. Sadek N, Bona J: Subsyndromal symptomatic depression: a new concept.
Depress Anxiety 2000, 12:30-39.
23. Cuijpers P, Smit F, Willemse G: Predicting the onset of major depression
in subjects with subtreshold depression in primary care: a prospective
study. Acta Psychiatr Scand 2004, 111:133-138.
24. Lyness JM, Heo M, Datto CJ, Ten Have TR, Katz IR, Drayer R, Reynolds CF,
Alexopoulos GS, Bruce ML: Outcomes of minor and subsyndromal
depression among elderly patients in primary care settings. Ann Intern
Med 2006, 144:496-504.
Pibernik-Okanović et al. Trials 2011, 12:17
http://www.trialsjournal.com/content/12/1/17
Page 7 of 825. Paile-Hyvarinen M, Wahlbeck K, Eriksson JG: Quality of life and metabolic
status in mildly depressed women with type 2 diabetes treated with
paroxetine: a single-blind randomised placebo controlled trial. BMC Fam
Pract 2003, 4:7.
26. Trozzolino L, Thomson PS, Tansman M, Azen SP: Effects of a psycho-
educational group on mood and glycemic control in adults with
diabetes and visual impairments. J Vis Impair Blind 2003, 97:230-239.
27. Pibernik-Okanovic M, Begic D, Ajdukovic D, Andrijasevic N, Metelko Z:
Psychoeducation versus treatment as usual in diabetic patients with
subthreshold depression: preliminary results of a randomized controlled
trial. Trials 2009, 10:78.
28. Lawlor DA, Hopker SW: The effectiveness of exercise as an intervention in
the management of depression: Systematic review and meta-regression
analysis of randomised controlled trials. BMJ 2001, 322:1-8.
29. Lysy Z, Da Costa D, Dasgupta K: The association of physical activity and
depression in Type 2 diabetes. Diabet Med 2008, 25:1133-1141.
30. Lin EHB, Katon W, Rutter C, Simon GE, Ludman EJ, von Korff M, Young B,
Oliver M, Ciechanowski PC, Kinder L, Walker E: Effects of Enhanced
Depression Treatment on Diabetes Self-Care. Ann Fam Med 2006, 4:46.
31. Pickup JC: Inflammation and activated innate immunity in the
pathogenesis of type 2 diabetes. Diabetes Care 2004, 27:813-823.
32. Kolb H, Mandrup-Poulsen T: An immune origin of type 2 diabetes?
Diabetologia 2005, 48:1038-1050.
33. Maes M: The cytokine hypothesis of depression: inflammation, oxidative
& nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive
treatments in depression. Neuro Endocrinol Lett 2008, 29:287-291,
Minireview.
34. Arroll B, Goodyear-Smith F, Kerse N, Fishman T, Gunn J: Effect of the
addition of a “help"question to two screening questions on specifity for
diagnosis of depression in general practice: diagnostic validity study.
BMJ 2005, 331(7521):884.
35. Poljicanin T, Pavlic-Renar I, Metelko Z: CroDiab NET - electronic diabetes
registry. Acta Med Croatica 2005, 59:185-189.
36. Rohde P, Lewinshon PM, Seeley JR: Comparability of telephone and
face-to-face interviews in assessing Axis I and II disorders. Am J Psychiatry
1997, 154:1593-1598.
37. Lewinsohn PM, Antonuccio DO, Steinmetz-Breckenridge JL, Teri L: The
Coping with Depression course: A psychoeducational intervention for unipolar
depression Eugene, OR: Castalia Publishing; 1984.
38. Levy JC, Matthews DR, Hermans MP: Correct homeostasis model
assessment (HOMA) evaluation uses the computer program. Diabetes
Care 1998, 21:2191-2192, (Letter).
39. Gavella M, Lipovac V, Car A, Vučić M, Sokolić L, Rakoš R: Serum sialic acid
in subjects with impaired glucose tolerance and in newly diagnosed
type 2 diabetic patients. Acta Diabetol 2003, 40:95-100.
doi:10.1186/1745-6215-12-17
Cite this article as: Pibernik-Okanović et al.: Does treatment of
subsyndromal depression improve depression and diabetes related
outcomes: protocol for a randomised controlled comparison of psycho-
education, physical exercise and treatment as usual. Trials 2011 12:17.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Pibernik-Okanović et al. Trials 2011, 12:17
http://www.trialsjournal.com/content/12/1/17
Page 8 of 8